Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

Slides:

Advertisements

Similar presentations

Volume 68, Pages S24-S28 (July 2005)

Advertisements

Kamyar Kalantar-Zadeh Kidney International

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Reduced renal function in patients with simple renal cysts

Steven Fishbane, Jeffrey S. Berns, M.D. Kidney International

Volume 57, Issue 5, Pages (May 2000)

E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P

Volume 69, Issue 5, Pages (March 2006)

Volume 55, Issue 3, Pages (March 1999)

Volume 73, Issue 1, Pages 3-5 (January 2008)

Anemia management in chronic kidney disease

C-reactive protein and dialysis access

Determinants of phosphorus mobilization during hemodialysis

Volume 57, Issue 5, Pages (May 2000)

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets David M. Spiegel, Kate Brady Kidney.

C-reactive protein and dialysis access

Volume 65, Issue 5, Pages (May 2004)

Volume 54, Issue 2, Pages (August 1998)

Volume 68, Issue 4, Pages (October 2005)

Rutger J.H. Maas, Jack F.M. Wetzels, Jeroen K.J. Deegens

Kamyar Kalantar-Zadeh Kidney International

Volume 76, Pages S50-S99 (August 2009)

Volume 71, Issue 1, Pages (January 2007)

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: Results of the CARE study Wajeh Y. Qunibi, Charles.

A new era in phosphate binder therapy: What are the options?

N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment Martina Franz, Wolfgang Woloszczuk, Walter.

The need for reliable serum parathyroid hormone measurements

Nephrology Crosswords: Hemodialysis

Use of vitamin D in chronic kidney disease patients

Volume 87, Issue 2, Pages (February 2015)

Gentamicin pharmacokinetics during slow daily home hemodialysis

Study of Heart and Renal Protection (SHARP)

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

The calcium–phosphorus in guidelines for CKD-MBD

Volume 69, Issue 3, Pages (February 2006)

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Blood pressure targets in hemodialysis patients

Volume 68, Pages S24-S28 (July 2005)

Volume 67, Issue 1, Pages (January 2005)

Volume 68, Issue 4, Pages (October 2005)

Volume 56, Pages S31-S37 (December 1999)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 87, Issue 3, Pages (March 2015)

Alternate-day dialysis may be needed for hemodialysis patients

Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia

The role of daily dialysis in the control of hyperphosphatemia

Reduced renal function in patients with simple renal cysts

Volume 67, Issue 3, Pages (March 2005)

Volume 55, Issue 5, Pages (May 1999)

Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients B. Bammens, P. Evenepoel, H. Keuleers,

Volume 54, Issue 1, Pages (July 1998)

Hemodialysis with high-calcium dialysate impairs cardiac relaxation

Current status of maintenance hemodialysis in Beijing, China

Volume 63, Issue 2, Pages (February 2003)

Volume 80, Issue 10, Pages (November 2011)

Volume 74, Issue 9, Pages (November 2008)

Volume 58, Issue 3, Pages (September 2000)

Volume 80, Issue 10, Pages (November 2011)

Volume 60, Issue 6, Pages (December 2001)

Recent developments in the management of secondary hyperparathyroidism

Volume 70, Issue 5, Pages (September 2006)

Strategies for iron supplementation: Oral versus intravenous

Volume 54, Issue 6, Pages (January 1998)

The International Pediatric Peritonitis Registry: Starting to walk

Increased fetuin-A levels following treatment with a vitamin D analog

N-methyl-2-pyridone-5-carboxamide: A novel uremic toxin?

Volume 61, Issue 4, Pages (April 2002)

Stephen Pastan, J. Michael Soucie, William M. McClellan

Presentation transcript:

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients Yutaka Takahashi, Araki Tanaka, Tsukasa Nakamura, Tsutomu Fukuwatari, Katsumi Shibata, Noriaki Shimada, Isao Ebihara, Hikaru Koide Kidney International Volume 65, Issue 3, Pages 1099-1104 (March 2004) DOI: 10.1111/j.1523-1755.2004.00482.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Effect of nicotinamide on blood nicotinamide adenine dinucleotide (NAD) concentration in hemodialysis patients.-2weeks indicates the start of pretreatment washout. *vs. 0week, P < 0.01. Kidney International 2004 65, 1099-1104DOI: (10.1111/j.1523-1755.2004.00482.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Changes in serum phosphorus levels with nicotinamide treatment in hemodialysis patients.*vs. 0week, P < 0.001; **vs. 0week, P < 0.01. Kidney International 2004 65, 1099-1104DOI: (10.1111/j.1523-1755.2004.00482.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Serum calcium levels in relation to nicotinamide treatment in hemodialysis patients. Kidney International 2004 65, 1099-1104DOI: (10.1111/j.1523-1755.2004.00482.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Effect of nicotinamide treatment on calcium-phosphorus product in hemodialysis patients.*vs. 0week, P < 0.0001; ** vs. 0week, P < 0.01. Kidney International 2004 65, 1099-1104DOI: (10.1111/j.1523-1755.2004.00482.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 5 Box and whisker plots showing serum intact parathyroid hormone (iPTH) levels in nicotinamide-treated hemodialysis patients.*vs. -2weeks, P < 0.05; **vs. 4weeks, P < 0.05. Kidney International 2004 65, 1099-1104DOI: (10.1111/j.1523-1755.2004.00482.x) Copyright © 2004 International Society of Nephrology Terms and Conditions